Prexasertib works by inhibiting CHK1, thereby preventing the repair of damaged DNA in cancer cells. This leads to an accumulation of DNA damage and ultimately induces cell death in cancer cells. The drug is particularly effective in cells with defective DNA repair mechanisms, such as those with mutations in BRCA1 or BRCA2.
